Astellas Pharma Inc
TSE:4503

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
TSE:4503
Watchlist
Price: 1 521 JPY -0.62% Market Closed
Market Cap: 2.8T JPY
Have any thoughts about
Astellas Pharma Inc?
Write Note

Astellas Pharma Inc
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Astellas Pharma Inc
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Astellas Pharma Inc
TSE:4503
Common Shares Outstanding
ÂĄ1.8B
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
-2%
Takeda Pharmaceutical Co Ltd
TSE:4502
Common Shares Outstanding
ÂĄ1.6B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
7%
Daiichi Sankyo Co Ltd
TSE:4568
Common Shares Outstanding
ÂĄ1.9B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
10%
Otsuka Holdings Co Ltd
TSE:4578
Common Shares Outstanding
ÂĄ540.4m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
S
Shionogi & Co Ltd
TSE:4507
Common Shares Outstanding
ÂĄ850.7m
CAGR 3-Years
41%
CAGR 5-Years
22%
CAGR 10-Years
10%
Chugai Pharmaceutical Co Ltd
TSE:4519
Common Shares Outstanding
ÂĄ1.6B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
12%
No Stocks Found

Astellas Pharma Inc
Glance View

Market Cap
2.7T JPY
Industry
Pharmaceuticals

Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.

Intrinsic Value
1 752.54 JPY
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Astellas Pharma Inc's Common Shares Outstanding?
Common Shares Outstanding
1.8B JPY

Based on the financial report for Sep 30, 2024, Astellas Pharma Inc's Common Shares Outstanding amounts to 1.8B JPY.

What is Astellas Pharma Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
-2%

Over the last year, the Common Shares Outstanding growth was 0%. The average annual Common Shares Outstanding growth rates for Astellas Pharma Inc have been -1% over the past three years , -1% over the past five years , and -2% over the past ten years .

Back to Top